**3.1 Neurology**

Alzheimer's disease (AD) may account for up to 80% of dementia cases and is a huge cost for society both economically and socially [11]. Although much advancement has been made in the underlying pathophysiological mechanisms of this disease as well as targeted approaches to therapy a significant barrier to any breakthrough occurs in the Identification of patients who will develop AD so that they are able to enroll in clinical trials at the appropriate time to examine the effectiveness of potential disease alternating treatment modalities. To combat this, a study was performed

using machine learning (ML) to assess advancement to dementia by two years using data from amyloid positron emission tomography scans [12]. The high accuracy that ML demonstrated relative to standard algorithms holds promise for the development of better individuals to be included in AD clinical trials with the hope that that this will optimize their design and lead to advancement of targeted disease therapies.
